Direct Treatment Costs for Patients with Lung Cancer from First Recurrence to Death in France
Beatrice Le Vu
Objective: To determine the direct treatment cost of lung cancer management from progression to death from the viewpoint of the hospital. Methods: A retrospective descriptive study was performed. Data from 100 patients who died of lung cancer and who had received treatment from four different types of hospital were used; the hospitals were public hospitals (teaching and non-teaching), private not-for-profit cancer centres, and private hospitals. Resource utilisation/cost data collected included the cost of diagnosis of the recurrence, the cost of hospitalisations or day care treatments and ambulatory surgery. All resources were valued in 2001 euros. Results: In France, the average cost per patient was Conclusion: The cost of treatment of recurrence of lung carcinoma is high, and is related to the number of lines of chemotherapy and the use of radiotherapy and surgery.
Antineoplastics, Cost-analysis, Lung-cancer, Pharmacoeconomics, Radiotherapy, Surgery
In order to set up a list of libraries that you have access to,
you must first login
or sign up.
Then set up a personal list of libraries from your profile page by
clicking on your user name at the top right of any screen.